These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21346233)

  • 1. Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response.
    Uram JN; Black CM; Flynn E; Huang L; Armstrong TD; Jaffee EM
    J Immunol; 2011 Apr; 186(7):3847-57. PubMed ID: 21346233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response.
    Ercolini AM; Ladle BH; Manning EA; Pfannenstiel LW; Armstrong TD; Machiels JP; Bieler JG; Emens LA; Reilly RT; Jaffee EM
    J Exp Med; 2005 May; 201(10):1591-602. PubMed ID: 15883172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
    Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
    J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen.
    Murata S; Ladle BH; Kim PS; Lutz ER; Wolpoe ME; Ivie SE; Smith HM; Armstrong TD; Emens LA; Jaffee EM; Reilly RT
    J Immunol; 2006 Jan; 176(2):974-83. PubMed ID: 16393983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice.
    Ercolini AM; Machiels JP; Chen YC; Slansky JE; Giedlen M; Reilly RT; Jaffee EM
    J Immunol; 2003 Apr; 170(8):4273-80. PubMed ID: 12682262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice.
    Wolpoe ME; Lutz ER; Ercolini AM; Murata S; Ivie SE; Garrett ES; Emens LA; Jaffee EM; Reilly RT
    J Immunol; 2003 Aug; 171(4):2161-9. PubMed ID: 12902523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination strategy determines the emergence and dominance of CD8+ T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer.
    Singh R; Paterson Y
    Cancer Res; 2006 Aug; 66(15):7748-57. PubMed ID: 16885378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
    Machiels JP; Reilly RT; Emens LA; Ercolini AM; Lei RY; Weintraub D; Okoye FI; Jaffee EM
    Cancer Res; 2001 May; 61(9):3689-97. PubMed ID: 11325840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines.
    Singh R; Paterson Y
    Cancer Immunol Immunother; 2007 Jun; 56(6):927-38. PubMed ID: 17131121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
    Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
    Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope.
    Otahal P; Hutchinson SC; Mylin LM; Tevethia MJ; Tevethia SS; Schell TD
    J Immunol; 2005 Jul; 175(2):700-12. PubMed ID: 16002665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
    Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
    Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD8⁺ Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response.
    Le DT; Ladle BH; Lee T; Weiss V; Yao X; Leubner A; Armstrong TD; Jaffee EM
    Int J Cancer; 2011 Aug; 129(3):636-47. PubMed ID: 20857491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
    Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
    Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential.
    Riedl P; Wieland A; Lamberth K; Buus S; Lemonnier F; Reifenberg K; Reimann J; Schirmbeck R
    J Immunol; 2009 Jul; 183(1):370-80. PubMed ID: 19542448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
    Reilly RT; Gottlieb MB; Ercolini AM; Machiels JP; Kane CE; Okoye FI; Muller WJ; Dixon KH; Jaffee EM
    Cancer Res; 2000 Jul; 60(13):3569-76. PubMed ID: 10910070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells.
    Weiss VL; Lee TH; Song H; Kouo TS; Black CM; Sgouros G; Jaffee EM; Armstrong TD
    PLoS One; 2012; 7(2):e31962. PubMed ID: 22359647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors.
    Nair RE; Kilinc MO; Jones SA; Egilmez NK
    J Immunol; 2006 Jun; 176(12):7325-34. PubMed ID: 16751376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of cross-reactive peptides using combinatorial libraries circumvents tolerance against Her-2/neu-immunodominant epitope.
    Lustgarten J; Dominguez AL; Pinilla C
    J Immunol; 2006 Feb; 176(3):1796-805. PubMed ID: 16424210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors.
    Cho HI; Niu G; Bradley N; Celis E
    Cancer Immunol Immunother; 2008 Nov; 57(11):1695-703. PubMed ID: 18253731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.